

# TARGETING RET IN LUNG CANCER: STATE OF THE ART IN TESTING AND THERAPEUTICS

## Chairs

Johan Vansteenkiste, Leuven, Belgium

Federico Cappuzzo, Rome, Italy

<b>SATURDAY, 27 MARCH 2021</b> 10:30 - 11:50 CET, CHANNEL 1		
<b>10:30</b>	<b>Live introduction</b>	Johan Vansteenkiste Leuven, Belgium
<b>10:35</b>	<b>Molecular diagnostics for detection of RET aberrations in non-small cell lung cancer: How, when and how often</b>	Frederique Penault-Llorca Clermont Ferrand, France
<b>10:50</b>	<b>Targeting the RET fusion in patients with advanced non-small cell lung cancer: Efficacy, toxicity, quality of life and cost</b>	Oliver Gautschi Lucerne, Switzerland
<b>11:10</b>	<b>Two clinical cases of patients with NSCLC harbouring RET abnormalities: Critical analysis of management according to ESMO Guidelines for NSCLC and NGS use, MCBS, ESCAT</b>	Antonio Passaro Milan, Italy
<b>11:30</b>	<b>Live conclusions</b>	Federico Cappuzzo Rome, Italy
<b>11:35</b>	<b>Q&amp;A and live discussion</b>	All speakers

This educational activity is provided by ESMO  
and co-supported by Lilly Oncology  
and Thermo Fisher Scientific.